This is the authors' abstract. We don't add key points for this paper.
OBJECTIVE: To examine whether serum interleukin-1β (IL-1β) or IL-1 receptor antagonist (IL-1Ra) levels are associated with disease activity or relapse risk in large vessel vasculitis (LVV), including giant cell arteritis (GCA) and Takayasu arteritis (TAK). METHODS: Twenty one patients with treatment-naive, active LVV (13 with GCA and 8 with TAK), and 14 healthy individuals were enrolled in the study. Serum levels of IL-1β, IL-1Ra, IL-2, IL-6, IL-12p40, IL-17, IL-23, IFN-γ, and TNF-α were measured. Association with C-reactive protein (CRP) levels, Indian Takayasu clinical activity score (ITAS-A), and relapse were analyzed. RESULTS: IL-1Ra levels were significantly higher in patients with with TAK (465.3 pg/mL) and GCA (384.9 pg/mL) compared to healthy individuals (170.4 pg/mL; p < 0.001). IL-6 levels were also elevated in LVV, while IL-1β and IFN-γ were increased only in GCA and IL-17 levels were increased only in TAK. IL-1Ra levels positively correlated with ITAS-A scores in TAK and with CRP levels in GCA. IL-6 correlated with CRP in both diseases; IL-1β and other cytokines showed no such association. During follow-up, six patients (five with GCA and one with TAK) experienced symptomatic relapse. In GCA, baseline IL-1Ra levels were significantly lower in those who relapsed compared to non-relapsed patients (270.8 vs. 616.4 pg/mL; p = 0.008). No significant difference in other cytokine levels were observed. Receiver operating characteristic analysis demonstrated that IL-1Ra levels >340.4 pg/mL could distinguish non-relapsed from relapsed cases (AUC = 0.95). CONCLUSION: Serum IL-1Ra levels correlate with CRP levels in GCA and ITAS-A scores in TAK and serve as a predictive biomarker for relapse.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: